GLP-1 agonists can play a pivotal role in disrupting the vicious cycle of obesity by supporting the growth of beneficial gut bacteria, which enhances gut mucosal integrity [47] and optimizes nutrient availability [48]. This evidence concerns the gene GLP1R and obesity disorder.